Biological degradation of cyclophosphamide and its occurrence in sewage water

Ecotoxicology and Environmental Safety

Volumn 36, Issue 2, 1997, Pages 174-179

  Steger Hartmann, T ^a   Kummerer K ^b   Hartmann, A ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Institute of Environmental Medicine and Hospital Epidemiology   (Germany)

^c Eidgenössische Technische Hochschule Zürich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

AMES TEST; ARTICLE; BIODEGRADATION; CANCER RISK; CYTOSTASIS; ECOTOXICITY; GENOTOXICITY; HOSPITAL WASTE; MUTAGENESIS; NONHUMAN; SEWAGE EFFLUENT; SEWAGE TREATMENT; URINARY EXCRETION; WASTE DISPOSAL; WATER SAMPLING;

EID: 0031105636     PISSN: 01476513     EISSN: None     Source Type: Journal    
DOI: 10.1006/eesa.1996.1506     Document Type: Article

References (29)

1. Bagley C. M. Jr., Bostick F. W., DeVita V. T. Jr. Clinical pharmacology of cyclophosphamide. Cancer Res. 33:1973;226-233.
2. Bodet C. A. I., Jorgensen J. H., Drutz D. J. Antibacterial activities of antineoplastic agents. Antimicrob. Agents Chemother. 28:1985;437-439.
3. Eliopoulos P., Mourelatos D., Dozi-Vassiliades J. Comparative study onSalmonellain vivo. Mutat. Res. 342:1995;141-146.
4. Ellenberger J., Mohn G. Mutagenic activity of cyclophosphamide, ifosfamide, and cyclophosphamide. Int. Arch. Occup. Environ. Health. 58:1975;151-155.
5. Gartiser S., Brinker L., Uhl A., Willmund R., Kümmerer K., Daschner F. Untersuchungen von Krankenhausabwasser am Beispiel des Universitätsklinikums Freiburg. Korres. Abw. 9:1994;1618-1624.
6. Gartiser S., Brinker L., Erbe T., Kümmerer K., Willmund R. Belastung von Krankenhausabwasser mit gefährlichen Stoffen im Sinne 7a WHG. Acta Hydrochim. Hydrobiol. 24:1996;90-97.
7. Gilard V., Martino R., Malet-Martino M.-C., Kutscher B., Müller A., Niemeyer U., Pohl J., Polymeropoulos E. E. Chemical and biological evaluation of hydrolysis products of cyclophosphamide. J. Med. Chem. 37:1994;3986-3993.
8. Giuliani F., Koller T., Würgler F. E., Widmer R. M. Detection of genotoxic activity in native hospital waste water by the umuC test. Mutat. Res. 368:1996;49-57.
9. Haas J. F., Kittelmann B., Mehnert W. H., Staneczek W., Möhner M., Kaldor J. M., Day N. E. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br. J. Cancer. 55:1987;213-218.
10. Hamilton-Miller J. M. T. Antimicrobial activity of 21 anti-neoplastic agents. Br. J. Cancer. 49:1984;367-369.
11. Hellmér L., Bolcsfoldi G. An evaluation of the E. coli K-12 uvrB/recA DNA repair host-mediated assay I. In vitro sensitivity of the bacteria to 61 compounds. Mutat. Res. 272:1992;145-160.
12. IARC Monographs on the evaluation of the Carcinogenic Risk of Chemicals to Man. 1975;IARC, Lyon. p. 135-156.
13. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. 1981;165-202 IARC, Lyon.
14. Jagun O., Ryan M., Waldron H. A. Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet. ii:1982;443-444.
15. Kümmerer K., Steger-Hartmann T., Baranyai A., Bürhaus I. Prüfung des biologischen Abbaus der Zytostatika Cyclophosphamid und Ifosfamid mit dem Closed Bottle Test (OECD 301 D). Zbl. Hyg. 198:1996;215-225.
16. Magiure R. J., Batchelor S. P., Sullivan C. A. Reduction of the efficiency of extraction of lipophilic chemicals from water by dissolved organic matter. Environ. Tox. Chem. 14:1995;389-393.
17. Nakamura S., Oda Y., Shimada T., Oki I., Sugimoto K. SOS-inducing activity of chemical carcinogens and mutagens inSalmonella typhimurium. Mutat. Res. 192:1987;239-246.
18. Nau H., Spielmann H., Mortler L. T., Winckler K., Riedel L., Obe G. Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives. Mutat. Res. 95:1982;105-118.
19. Neu H. J. Ist organische Spurenanalyse in Abwasser machbar. Hewlett-Packard GmbH. Buch der Umweltanalytik - Band 2. 1991;27-36 GIT Verlag GmbH, Darmstadt.
20. Nieweg R. M. B., de Boer M., Dubbleman R. C., Gall H. E., Hesselman G. M., Lenssen P. C. H. P., van Maanen L. W. G. M., Majoor P. P. W. F. M., Ouerkerk J., Slegt J. H. Safe handling of antineoplastic drugs. Cancer Nurs. 17:1994;501-511.
21. Oda Y., Nakamura S., Oki I., Kato T., Shinagawa H. Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. Mutat. Res. 147:1985;219-229.
22. OECD, 1992, OECD Guideline for Testing of Chemicals (302 B): Zahn-Wellens/EMPA Test, OECD.
23. Richardson M. L., Bowron J. M. The fate of pharmaceutical chemicals in the aquatic environment. J. Pharm. Pharmacol. 37:1985;1-12.
24. Schöberl P. Coupling the OECD confirmatory test with continuous ecotoxicity test. Communication 1. Modification of the OECD confirmatory test (sewage treatment plant simulation model). Tens. Surf. Deterg. 28:1991;97-105.
25. Sessink P. J. M., Boer K. A., Scheefhals A. P. H., Anzion R. B. M., Bos R. P. Occupational exposure to antineoplastic agents at several departments in a hospital. Int. Arch. Occup. Environ. Health. 64:1992;105-112.
26. Steger-Hartmann T., Kümmerer K., Schecker J. Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by two-step solid-phase extraction and gas chromatography-mass spectrometry. J. Chromatogr. A726:1996;179-184.
27. Travis L. B., Curtis R. E., Glimelius B., Holowaty E. J., van Leuwen F. E., Lynch C. F., Hagenbeek A., Stovall M., Banks P. M., Adami J., Gospodarowicz M. K., Wacholder S., Inskip P. D., Tucker M. A., Boice J. D. Jr. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 87:1995;524-530.
28. Vaccari P. L., Tonat K., DeChristoforo R., Gallelli J. F., Zimmermann P. F. Disposal of antineoplastic wastes at the National Institutes of Health. Am. J. Hosp. Pharm. 41:1984;87-93.
29. Wall R. L., Clausen K. P. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N. Engl. J. Med. 293:1975;271-273.